The group's principal activities are to discover, develop and commercialize novel therapeutic and diagnostic systems for the treatment of viral diseases. The group's core technology revolves around a biologically active linear protein, thymus nuclear protein (tnp). The group's main focus has been the development of a treatment to stop the progression of the human immunodeficiency virus (HIV), which is the causative agent in aids.
